Nectin Therapeutics
Agent21 out of 100, Bottom 25%. Agent Readiness. Open the scores section.Agent Readiness: 21/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Trust67 out of 100, Above median. Data Trust. Open the scores section.Data Trust: 67/100. Above median. Measured by StartupHub.ai. Median 61.Biotech company developing next-generation immunotherapy agents to unlock the immune system.
About
Nectin Therapeutics develops immuno-oncology and ADC breakthrough therapies to overcome tumor escape and resistance mechanisms. Their diverse pipeline includes novel immuno-oncology antibodies and ADCs, with an anti-PVR asset currently in Phase 1 clinical trials. They aim to address difficult-to-treat cancers for patients who do not respond to approved immuno-oncology therapies.
Similar companies
Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.
Shares Life Sciences, Biotech
AI-powered patient-centric drug simulations to accelerate and de-risk drug development.
Shares Life Sciences, Clinical Trials
AI-powered blood test for early cancer detection and subtyping.
Shares Life Sciences, Biotech
Omnix Medical is developing a novel platform for advanced wound care management.
Shares Life Sciences, HealthTech
Develops a platform for individual drug customization using aptamers for cancer treatment.
Shares Life Sciences, Cancer
Biopharmaceutical company developing innovative punctal plug technology for eye disease therapies.
Shares Life Sciences, Biotech
Key facts
- Website
- nectintx.com
- Founded
- 2016
- Employees
- 11
- Total funding
- $64M (Series C)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 6 May 2024 | Series C | $10M | Guangzhou-Israel Biotechnology Fund (GIBF) |
| 28 Feb 2024 | Grant | $3M | EU EIC Accelerator |
| 30 Nov 2022 | Series B | $25M | Peregrine Ventures, Israel Biotech Fund |
| 9 Mar 2022 | Series A | $5M | Cancer Focus Fund |
| 1 May 2021 | Series A | $15M | |
| 20 Jul 2020 | Seed | $6M |
Tech stack
Detected on nectintx.com, last scanned 30 Jul 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4, Segment
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is Nectin Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Nectin Therapeutics is 67 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Nectin Therapeutics raised?
Nectin Therapeutics has raised a total of $64M in funding. The most recent round on record is Series C.
How many employees does Nectin Therapeutics have?
Nectin Therapeutics has approximately 11 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for Nectin Therapeutics:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
